FENC
Price
$5.54
Change
-$0.09 (-1.60%)
Updated
Jan 17 closing price
Capitalization
152.05M
72 days until earnings call
RGLS
Price
$1.24
Change
-$0.04 (-3.12%)
Updated
Jan 17 closing price
Capitalization
81.22M
60 days until earnings call
Ad is loading...

FENC vs RGLS

Header iconFENC vs RGLS Comparison
Open Charts FENC vs RGLSBanner chart's image
Fennec Pharmaceuticals
Price$5.54
Change-$0.09 (-1.60%)
Volume$36.24K
Capitalization152.05M
Regulus Therapeutics
Price$1.24
Change-$0.04 (-3.12%)
Volume$330.14K
Capitalization81.22M
FENC vs RGLS Comparison Chart
Loading...
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FENC vs. RGLS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FENC is a Hold and RGLS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (FENC: $5.54 vs. RGLS: $1.24)
Brand notoriety: FENC and RGLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FENC: 29% vs. RGLS: 114%
Market capitalization -- FENC: $152.05M vs. RGLS: $81.22M
FENC [@Biotechnology] is valued at $152.05M. RGLS’s [@Biotechnology] market capitalization is $81.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FENC’s FA Score shows that 0 FA rating(s) are green whileRGLS’s FA Score has 1 green FA rating(s).

  • FENC’s FA Score: 0 green, 5 red.
  • RGLS’s FA Score: 1 green, 4 red.
According to our system of comparison, RGLS is a better buy in the long-term than FENC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FENC’s TA Score shows that 1 TA indicator(s) are bullish while RGLS’s TA Score has 3 bullish TA indicator(s).

  • FENC’s TA Score: 1 bullish, 3 bearish.
  • RGLS’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, RGLS is a better buy in the short-term than FENC.

Price Growth

FENC (@Biotechnology) experienced а -6.26% price change this week, while RGLS (@Biotechnology) price change was -12.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

FENC is expected to report earnings on May 08, 2025.

RGLS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FENC($152M) has a higher market cap than RGLS($81.2M). FENC YTD gains are higher at: -12.342 vs. RGLS (-21.519). FENC has higher annual earnings (EBITDA): 3.02M vs. RGLS (-41.03M). RGLS has more cash in the bank: 87.3M vs. FENC (40.3M). RGLS has less debt than FENC: RGLS (476K) vs FENC (32.1M). FENC has higher revenues than RGLS: FENC (49.3M) vs RGLS (0).
FENCRGLSFENC / RGLS
Capitalization152M81.2M187%
EBITDA3.02M-41.03M-7%
Gain YTD-12.342-21.51957%
P/E Ratio64.14N/A-
Revenue49.3M0-
Total Cash40.3M87.3M46%
Total Debt32.1M476K6,744%
FUNDAMENTALS RATINGS
FENC vs RGLS: Fundamental Ratings
FENC
RGLS
OUTLOOK RATING
1..100
6358
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5864
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGLS's Valuation (20) in the Pharmaceuticals Other industry is significantly better than the same rating for FENC (91) in the Biotechnology industry. This means that RGLS’s stock grew significantly faster than FENC’s over the last 12 months.

RGLS's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as FENC (100) in the Biotechnology industry. This means that RGLS’s stock grew similarly to FENC’s over the last 12 months.

RGLS's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as FENC (100) in the Biotechnology industry. This means that RGLS’s stock grew similarly to FENC’s over the last 12 months.

FENC's Price Growth Rating (58) in the Biotechnology industry is in the same range as RGLS (64) in the Pharmaceuticals Other industry. This means that FENC’s stock grew similarly to RGLS’s over the last 12 months.

FENC's P/E Growth Rating (97) in the Biotechnology industry is in the same range as RGLS (100) in the Pharmaceuticals Other industry. This means that FENC’s stock grew similarly to RGLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FENCRGLS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 12 days ago
83%
Bullish Trend 12 days ago
88%
Momentum
ODDS (%)
Bearish Trend 12 days ago
80%
Bearish Trend 12 days ago
87%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
81%
Bearish Trend 12 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
82%
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
Bullish Trend 28 days ago
77%
Bullish Trend 25 days ago
85%
Declines
ODDS (%)
Bearish Trend 14 days ago
79%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 12 days ago
87%
View a ticker or compare two or three
Ad is loading...
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEAAX46.530.61
+1.33%
Fidelity Advisor Emerging Asia A
AASSX23.320.14
+0.60%
American Beacon Small Cp Val Adv
PMARX12.260.05
+0.41%
Pioneer Equity Premium Income A
HSISX10.780.03
+0.28%
Hartford Schroders Sust Intl Core I
GGHYX38.22-0.22
-0.57%
Invesco Health Care Y

FENC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FENC has been loosely correlated with SCPX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if FENC jumps, then SCPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FENC
1D Price
Change %
FENC100%
-1.60%
SCPX - FENC
39%
Loosely correlated
-1.86%
KYMR - FENC
32%
Poorly correlated
+0.79%
ATXS - FENC
31%
Poorly correlated
-3.23%
BEAM - FENC
30%
Poorly correlated
+0.17%
AVIR - FENC
30%
Poorly correlated
+1.20%
More

RGLS and

Correlation & Price change

A.I.dvisor tells us that RGLS and SPRY have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGLS and SPRY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
-3.12%
SPRY - RGLS
28%
Poorly correlated
+3.20%
NAUT - RGLS
26%
Poorly correlated
+1.58%
FENC - RGLS
25%
Poorly correlated
-1.60%
IDYA - RGLS
25%
Poorly correlated
-2.38%
CARA - RGLS
25%
Poorly correlated
+1.09%
More